Introducing Gitte Pedersen, Co-Founder and Chief Executive Officer, Genomic Expression, based in Boston, Mass.

Gitte Pedersen founded Genomic Expression with her brother when their parents got diagnosed with cancer. Prior to Genomic Expression, she operated Proximity Ventures and advised companies and Danish Ministry of Foreign Affairs brining in +$1B deals to Danish Biotech companies. She worked at Novo Nordisk in a number of management positions and brought multiple product to market worldwide. She has a master in Chemical Engineering and a bachelor in International Trade.

Genomic Expression is a commercial-stage RNA Platform For Next Generation Cures. By analyzing RNA, we can detect disease, monitor health and design next generation cures. Focus on women cancer and infectious disease. Regulatory approvals obtained. Recurring customers, partnered with handful of clinical sites including Rutgers cancer center and US National Cancer Institute. Top 10 of the XTC, presented for Richard Branson at Necker island, won the Lyfebulb and the EUTop50 award, and presented at the UN and the European Parliament, semi-finals of XPRIZE.

Meet Gitte and learn more about Genomic Expression’s groundbreaking work by completing your RSVP.

Introducing Tim Peara, President, Bridge Therapeutics

Bridge Therapeutics (“Safe alternatives to Opioids”) is a quick-to-sales biopharma company disrupting the $35B+ markets for pain and addiction. Bridge is tackling a root cause of the Opioid crisis by providing strong pain relief with low risk of addiction or overdose. Proven ingredients and best-in-class delivery technology should allow Bridge to obtain FDA approval quickly while erecting economic barriers to entry around therapies. Bridge’s team is relevant, capable and experienced, guiding it to become a multi-billion-dollar company.

Bridge Therapeutics CEO Tim Peara brings deep experience in business development and finance, building departments for large companies as well as developing projects and technology companies, both in the USA and abroad. For 20 years Tim has developed technology start-ups (Greenfuel Technologies) and energy projects (Koch, GE) preceded by 14 years on Wall Street as an investment strategist (Prudential, Lehman). He earned a BA from Wesleyan University, Connecticut and an MBA from the University of Chicago’s Booth School of Business.

Meet Tim and learn more about Bridge Therapeutics’ groundbreaking work by completing your RSVP.